

Luis Alberto Diaz Jr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5784042/publications.pdf>

Version: 2024-02-01

202
papers

75,252
citations

4120

87
h-index

2500

196
g-index

213
all docs

213
docs citations

213
times ranked

72254
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	7.7	28
2	Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 659-670.	5.1	282
3	Clinical validation of a next-generation sequencing-based multi-cancer early detection "liquid biopsy" blood test in over 1,000 dogs using an independent testing set: The CANcer Detection in Dogs (CANDiD) study. <i>PLoS ONE</i> , 2022, 17, e0266623.	1.1	20
4	Automated next-generation profiling of genomic alterations in human cancers. <i>Nature Communications</i> , 2022, 13, .	5.8	8
5	Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy "Authors' reply. <i>Lancet Oncology</i> , The, 2022, 23, e246.	5.1	1
6	PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2363-2376.	13.9	588
7	Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing?. <i>Annals of Internal Medicine</i> , 2021, 174, 353-361.	2.0	124
8	DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. <i>Cancer Cell</i> , 2021, 39, 96-108.e6.	7.7	153
9	Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis. <i>Nature Communications</i> , 2021, 12, 338.	5.8	64
10	A Decade of <i>Cancer Discovery</i> . <i>Cancer Discovery</i> , 2021, 11, 795-797.	7.7	2
11	CD4 T Cell-Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair-Deficient Tumors. <i>Cancer Discovery</i> , 2021, 11, 1844-1859.	7.7	37
12	The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors. <i>New England Journal of Medicine</i> , 2021, 384, 1168-1170.	13.9	137
13	Horizons in Veterinary Precision Oncology: Fundamentals of Cancer Genomics and Applications of Liquid Biopsy for the Detection, Characterization, and Management of Cancer in Dogs. <i>Frontiers in Veterinary Science</i> , 2021, 8, 664718.	0.9	21
14	Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 665-677.	5.1	110
15	Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures. , 2021, 9, e002345.		7
16	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. <i>Nature Communications</i> , 2021, 12, 3770.	5.8	68
17	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. <i>Cell</i> , 2021, 184, 4032-4047.e31.	13.5	131
18	Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Patients With Cancer. <i>JAMA Oncology</i> , 2021, 7, 1686.	3.4	11

#	ARTICLE	IF	CITATIONS
19	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1683-1692.	3.0	66
20	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 2698-2709.	0.8	83
21	Clonal hematopoiesis is associated with risk of severe Covid-19. <i>Nature Communications</i> , 2021, 12, 5975.	5.8	81
22	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma. <i>JAMA Oncology</i> , 2020, 6, 60.	3.4	112
23	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1-10.	0.8	1,740
24	Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. <i>Journal of Clinical Oncology</i> , 2020, 38, 11-19.	0.8	623
25	Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. <i>Targeted Oncology</i> , 2020, 15, 11-24.	1.7	65
26	Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers. <i>Scientific Reports</i> , 2020, 10, 17769.	1.6	35
27	Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2207-2218.	13.9	1,513
28	Chemotherapy and COVID-19 Outcomes in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3538-3546.	0.8	195
29	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. <i>Nature Genetics</i> , 2020, 52, 1219-1226.	9.4	367
30	Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3271-3279.	3.2	118
31	Fragment Size Analysis May Distinguish Clonal Hematopoiesis from Tumor-Derived Mutations in Cell-Free DNA. <i>Clinical Chemistry</i> , 2020, 66, 616-618.	1.5	35
32	Evaluation of <i>POLE/POLD1</i> Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes. <i>JAMA Oncology</i> , 2020, 6, 589.	3.4	8
33	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6160-6169.	3.2	73
34	Hey CIRI, What's My Prognosis? <i>Cell</i> , 2019, 178, 518-520.	13.5	6
35	Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. <i>Journal of Clinical Oncology</i> , 2019, 37, 3546-3555.	0.8	78
36	Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 1574-1579.	1.6	33

#	ARTICLE	IF	CITATIONS
37	Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 5250-5259.	3.2	46
38	Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates. , 2019, 7, 123.		2
39	Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. <i>Science</i> , 2019, 364, 485-491.	6.0	395
40	Majority of <i>B2M</i> -Mutant and <i>-Deficient</i> Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	61
41	Immunotherapy in colorectal cancer: rationale, challenges and potential. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 361-375.	8.2	1,039
42	Managing Clonal Hematopoiesis in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 7-11.	0.8	60
43	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 286-295.	0.8	397
44	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. , 2019, 7, 40.		42
45	Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine Carcinoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-7.	1.5	4
46	Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade. <i>Clinical Cancer Research</i> , 2019, 25, 7024-7034.	3.2	104
47	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. <i>Nature Medicine</i> , 2019, 25, 1928-1937.	15.2	485
48	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. <i>Modern Pathology</i> , 2019, 32, 110-121.	2.9	28
49	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018, 359, 926-930.	6.0	1,872
50	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. <i>Clinical Cancer Research</i> , 2018, 24, 1326-1336.	3.2	281
51	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	178
52	A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 316-325.	3.2	17
53	Acquired resistance to immunotherapy in MMR-D pancreatic cancer. , 2018, 6, 127.		27
54	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. <i>Cancer Discovery</i> , 2018, 8, 1540-1547.	7.7	138

#	ARTICLE	IF	CITATIONS
55	A machine learning approach for somatic mutation discovery. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	80
56	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. <i>ELife</i> , 2018, 7, .	2.8	118
57	Cancer-Associated Mutations in Endometriosis without Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 1835-1848.	13.9	451
58	Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations. <i>Cancer Discovery</i> , 2017, 7, 188-201.	7.7	997
59	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017, 357, 409-413.	6.0	4,945
60	A Blueprint to Advance Colorectal Cancer Immunotherapies. <i>Cancer Immunology Research</i> , 2017, 5, 942-949.	1.6	63
61	Direct detection of early-stage cancers using circulating tumor DNA. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	808
62	Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. <i>Cancer Medicine</i> , 2017, 6, 1552-1562.	1.3	19
63	The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2017, 23, 2471-2477.	3.2	154
64	Diagnostic potential of tumor DNA from ovarian cyst fluid. <i>ELife</i> , 2016, 5, .	2.8	30
65	Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 18-26.	0.6	16
66	Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e515-e520.	0.9	19
67	Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. <i>Oncologist</i> , 2016, 21, 1200-1211.	1.9	211
68	Non-infectious environmental antigens as a trigger for the initiation of an autoimmune skin disease. <i>Autoimmunity Reviews</i> , 2016, 15, 923-930.	2.5	26
69	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. <i>Science Translational Medicine</i> , 2016, 8, 346ra92.	5.8	1,036
70	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2016, 375, 1749-1755.	13.9	1,668
71	Overlapping IgG4 Responses to Self- and Environmental Antigens in Endemic Pemphigus Foliaceus. <i>Journal of Immunology</i> , 2016, 196, 2041-2050.	0.4	26
72	PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.. <i>Journal of Clinical Oncology</i> , 2016, 34, 195-195.	0.8	39

#	ARTICLE	IF	CITATIONS
73	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , 2015, 372, 2509-2520.	13.9	7,696
74	A First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1281-1288.	3.2	50
75	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , 2015, 373, 1979-1979.	13.9	314
76	Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9967-9972.	3.3	41
77	A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. <i>Gastroenterology</i> , 2015, 149, 1501-1510.	0.6	376
78	Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 489-498.	1.1	59
79	Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. <i>Nature Communications</i> , 2015, 6, 7686.	5.8	393
80	Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. <i>Science Translational Medicine</i> , 2015, 7, 293ra104.	5.8	372
81	Genetic Classification of Gliomas: Refining Histopathology. <i>Cancer Cell</i> , 2015, 28, 9-11.	7.7	40
82	Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9704-9709.	3.3	317
83	Personalized genomic analyses for cancer mutation discovery and interpretation. <i>Science Translational Medicine</i> , 2015, 7, 283ra53.	5.8	347
84	The genomic landscape of response to EGFR blockade in colorectal cancer. <i>Nature</i> , 2015, 526, 263-267.	13.7	398
85	Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4293-4300.	0.8	87
86	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. <i>Science Translational Medicine</i> , 2014, 6, 224ra24.	5.8	3,665
87	Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 15-24.	1.5	91
88	A randomized pilot trial of a telephone-based couples intervention for physical intimacy and sexual concerns in colorectal cancer. <i>Psycho-Oncology</i> , 2014, 23, 1005-1013.	1.0	64
89	Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11774-11779.	3.3	578
90	Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. , 2014, 2, 42.		186

#	ARTICLE	IF	CITATIONS
91	A Single Institution's 26-Year Experience With Nonfunctional Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2014, 259, 204-212.	2.1	138
92	Detection of Somatic TP53 Mutations in Tampons of Patients With High-Grade Serous Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2014, 124, 881-885.	1.2	44
93	Intratumoral injection of <i>Clostridium novyi</i> -NT spores induces antitumor responses. <i>Science Translational Medicine</i> , 2014, 6, 249ra111.	5.8	285
94	Gastrointestinal ostomies and sexual outcomes: a comparison of colorectal cancer patients by ostomy status. <i>Supportive Care in Cancer</i> , 2014, 22, 461-468.	1.0	51
95	Liquid Biopsies: Genotyping Circulating Tumor DNA. <i>Journal of Clinical Oncology</i> , 2014, 32, 579-586.	0.8	1,811
96	Circulating tumor DNA moves further into the spotlight. <i>Genome Medicine</i> , 2014, 6, 35.	3.6	23
97	Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. <i>Nature Communications</i> , 2014, 5, 5006.	5.8	149
98	The Early Detection of Pancreatic Cancer: What Will It Take to Diagnose and Treat Curable Pancreatic Neoplasia?. <i>Cancer Research</i> , 2014, 74, 3381-3389.	0.4	207
99	Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment. <i>Clinical Cancer Research</i> , 2014, 20, 2476-2484.	3.2	140
100	The Clinical Utility of Biomarkers in the Management of Pancreatic Adenocarcinoma. <i>Seminars in Radiation Oncology</i> , 2014, 24, 67-76.	1.0	13
101	Baseline Hemoglobin-A1c Impacts Clinical Outcomes in Patients With Pancreatic Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 50-57.	2.3	16
102	Tracking tumor resistance using 'liquid biopsies'. <i>Nature Medicine</i> , 2013, 19, 676-677.	15.2	34
103	Cancer Genome Landscapes. <i>Science</i> , 2013, 339, 1546-1558.	6.0	6,507
104	<i>TERT</i> Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine. <i>Cancer Research</i> , 2013, 73, 7162-7167.	0.4	214
105	Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. <i>Cancer</i> , 2013, 119, 4137-4144.	2.0	161
106	The Clinical Potential of Circulating Tumor Cells and Circulating Tumor-Associated Cellular Elements in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 303-311.	1.0	0
107	<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6021-6026.	3.3	1,202
108	Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers. <i>Science Translational Medicine</i> , 2013, 5, 167ra4.	5.8	264

#	ARTICLE	IF	CITATIONS
109	IgG autoantibody subclass analysis as a tool to differentiate epidermolysis bullosa acquisita with overlapping features of bullous systemic lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, e34-e36.	0.6	9
110	Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. <i>Nature Genetics</i> , 2013, 45, 12-17.	9.4	374
111	Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. <i>Investigational New Drugs</i> , 2013, 31, 345-354.	1.2	17
112	Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. <i>Cancer Discovery</i> , 2013, 3, 658-673.	7.7	585
113	Neuroendocrine Liver Metastasis Treated by Using Intraarterial Therapy: Volumetric Functional Imaging Biomarkers of Early Tumor Response and Survival. <i>Radiology</i> , 2013, 266, 502-513.	3.6	54
114	Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer. <i>Journal of Immunotherapy</i> , 2013, 36, 382-389.	1.2	460
115	Evolutionary dynamics of cancer in response to targeted combination therapy. <i>ELife</i> , 2013, 2, e00747.	2.8	516
116	First report of the correlation of PET Response Criteria in Solid Tumors (PERCIST) criteria and pathologic change in patients with rectal cancer treated with neoadjuvant radiation.. <i>Journal of Clinical Oncology</i> , 2013, 31, 261-261.	0.8	1
117	Cancer detection using whole-genome sequencing of cell free DNA. <i>Oncotarget</i> , 2013, 4, 1119-1120.	0.8	11
118	Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA. <i>Oncotarget</i> , 2013, 4, 1856-1857.	0.8	39
119	Takotsubo Cardiomyopathy and Fluorouracil: Case Report and Review of the Literature. <i>Journal of Clinical Oncology</i> , 2012, 30, e11-e14.	0.8	72
120	Evaluation of Clostridium novyi NT spores in dogs with naturally occurring tumors. <i>American Journal of Veterinary Research</i> , 2012, 73, 112-118.	0.3	54
121	Clinicopathologic Comparison of High-Dose-Rate Endorectal Brachytherapy versus Conventional Chemoradiotherapy in the Neoadjuvant Setting for Resectable Stages II and III Low Rectal Cancer. <i>International Journal of Surgical Oncology</i> , 2012, 2012, 1-12.	0.3	13
122	Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing. <i>Science Translational Medicine</i> , 2012, 4, 162ra154.	5.8	557
123	Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. <i>Journal of Neuro-Oncology</i> , 2012, 110, 279-285.	1.4	29
124	Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. <i>Practical Radiation Oncology</i> , 2012, 2, 77-85.	1.1	28
125	Treating Patients with Colon Cancer Liver Metastasis: A Nationwide Analysis of Therapeutic Decision Making. <i>Annals of Surgical Oncology</i> , 2012, 19, 3668-3676.	0.7	26
126	Frequent <i>ATRX</i> , <i>CIC</i> , <i>FUBP1</i> and <i>IDH1</i> mutations refine the classification of malignant gliomas. <i>Oncotarget</i> , 2012, 3, 709-722.	0.8	532

#	ARTICLE	IF	CITATIONS
127	The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. <i>Nature</i> , 2012, 486, 537-540.	13.7	1,506
128	Genetically Defined Subsets of Human Pancreatic Cancer Show Unique <i>In Vitro</i> Chemosensitivity. <i>Clinical Cancer Research</i> , 2012, 18, 6519-6530.	3.2	60
129	Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas. <i>Journal of Neuro-Oncology</i> , 2012, 109, 123-127.	1.4	38
130	A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 415-424.	1.1	39
131	A phase I/IIA safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers.. <i>Journal of Clinical Oncology</i> , 2012, 30, 233-233.	0.8	2
132	Integrated next-generation sequencing and patient-derived xenografts to personalized cancer treatment.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3068-3068.	0.8	0
133	Diagnosis and Clinical Features of Pemphigus Foliaceus. <i>Dermatologic Clinics</i> , 2011, 29, 405-412.	1.0	99
134	Pathogenesis of Endemic Pemphigus Foliaceus. <i>Dermatologic Clinics</i> , 2011, 29, 413-418.	1.0	22
135	<i>DAXX</i> / <i>ATRX</i> , <i>MEN1</i> , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors. <i>Science</i> , 2011, 331, 1199-1203.	6.0	1,504
136	TNF-blockade in patients with advanced hormone refractory prostate cancer. <i>Investigational New Drugs</i> , 2011, 29, 192-194.	1.2	5
137	Detection of Tumor DNA at the Margins of Colorectal Cancer Liver Metastasis. <i>Clinical Cancer Research</i> , 2011, 17, 3551-3557.	3.2	42
138	Understanding the Enemy. <i>Science Translational Medicine</i> , 2011, 3, 98ps37.	5.8	4
139	Recurrent <i>GNAS</i> Mutations Define an Unexpected Pathway for Pancreatic Cyst Development. <i>Science Translational Medicine</i> , 2011, 3, 92ra66.	5.8	703
140	The C5a Receptor on Mast Cells Is Critical for the Autoimmune Skin-blistering Disease Bullous Pemphigoid. <i>Journal of Biological Chemistry</i> , 2011, 286, 15003-15009.	1.6	66
141	Dual Targets for Mouse Mast Cell Protease-4 in Mediating Tissue Damage in Experimental Bullous Pemphigoid. <i>Journal of Biological Chemistry</i> , 2011, 286, 37358-37367.	1.6	55
142	Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 21188-21193.	3.3	585
143	Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia. <i>Leukemia</i> , 2011, 25, 1908-1910.	3.3	28
144	IgE, IgM, and IgG4 Anti-Desmoglein 1 Autoantibody Profile in Endemic Pemphigus Foliaceus (Fogo) Tj ETQq0 0 0 rgBT_/Overlock 10 Tf 50	0.3	34

#	ARTICLE	IF	CITATIONS
145	A Robust Approach to Enhance Tumor-selective Accumulation of Nanoparticles. <i>Oncotarget</i> , 2011, 2, 59-68.	0.8	40
146	IgH gene rearrangements as plasma biomarkers in Non-Hodgkin's Lymphoma patients. <i>Oncotarget</i> , 2011, 2, 178-185.	0.8	61
147	Systemic use of tumor necrosis factor alpha as an anticancer agent. <i>Oncotarget</i> , 2011, 2, 739-751.	0.8	151
148	Disappearing Colorectal Liver Metastases after Chemotherapy: Should we be Concerned?. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 1691-1700.	0.9	111
149	Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. <i>Nature</i> , 2010, 464, 610-614.	13.7	470
150	The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center. <i>Clinical Cancer Research</i> , 2010, 16, 5997-6003.	3.2	38
151	An Insight into the Sialotranscriptome of <i>Simulium nigrimanum</i> , a Black Fly Associated with Fogo Selvagem in South America. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 82, 1060-1075.	0.6	36
152	Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing. <i>Science Translational Medicine</i> , 2010, 2, 20ra14.	5.8	447
153	The Resident Retreat for Future Academicians. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1775-1777.	0.3	3
154	The Thomsen-Friedenreich Antigen-Binding Lectin Jacalin Interacts with Desmoglein-1 and Abrogates the Pathogenicity of Pemphigus Foliaceus Autoantibodies In Vivo. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2773-2780.	0.3	4
155	p38MAPK Signaling and Desmoglein-3 Internalization Are Linked Events in Pemphigus Acantholysis. <i>Journal of Biological Chemistry</i> , 2010, 285, 8936-8941.	1.6	91
156	Subcutaneous Metastatic Adenocarcinoma: An Unusual Presentation of Colon Cancer – Case Report and Literature Review. <i>Case Reports in Oncology</i> , 2010, 3, 386-390.	0.3	13
157	Frequent Mutations of Chromatin Remodeling Gene <i>ARID1A</i> in Ovarian Clear Cell Carcinoma. <i>Science</i> , 2010, 330, 228-231.	6.0	1,090
158	Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1284-1285.	3.0	79
159	Biphasic Activation of p38MAPK Suggests That Apoptosis Is a Downstream Event in Pemphigus Acantholysis. <i>Journal of Biological Chemistry</i> , 2009, 284, 12524-12532.	1.6	61
160	Involvement of the Apoptotic Mechanism in Pemphigus Foliaceus Autoimmune Injury of the Skin. <i>Journal of Immunology</i> , 2009, 182, 711-717.	0.4	50
161	A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3964-3969.	3.3	267
162	Mutations of IDH1 and IDH2 are not detected in brain metastases of colorectal cancer. <i>Journal of Neuro-Oncology</i> , 2009, 94, 297-297.	1.4	8

#	ARTICLE	IF	CITATIONS
163	Development of an IgG4-Based Predictor of Endemic Pemphigus Foliaceus (Fogo Selvagem). <i>Journal of Investigative Dermatology</i> , 2009, 129, 110-118.	0.3	47
164	Antigen Selection of Anti-DSG1 Autoantibodies During and Before the Onset of Endemic Pemphigus Foliaceus. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2823-2834.	0.3	22
165	Sensitive digital quantification of DNA methylation in clinical samples. <i>Nature Biotechnology</i> , 2009, 27, 858-863.	9.4	317
166	Glucose Deprivation Contributes to the Development of <i>KRAS</i> Pathway Mutations in Tumor Cells. <i>Science</i> , 2009, 325, 1555-1559.	6.0	797
167	Complement and cutaneous autoimmune blistering diseases. <i>Immunologic Research</i> , 2008, 41, 223-232.	1.3	24
168	An Integrated Genomic Analysis of Human Glioblastoma Multiforme. <i>Science</i> , 2008, 321, 1807-1812.	6.0	5,230
169	Circulating mutant DNA to assess tumor dynamics. <i>Nature Medicine</i> , 2008, 14, 985-990.	15.2	2,207
170	Induction of p38MAPK and HSP27 Phosphorylation in Pemphigus Patient Skin. <i>Journal of Investigative Dermatology</i> , 2008, 128, 738-740.	0.3	62
171	The IgM Anti-Desmoglein 1 Response Distinguishes Brazilian Pemphigus Foliaceus (Fogo Selvagem) from Other Forms of Pemphigus. <i>Journal of Investigative Dermatology</i> , 2008, 128, 667-675.	0.3	50
172	E-cadherin Is an Additional Immunological Target for Pemphigus Autoantibodies. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1710-1718.	0.3	56
173	Advances in pemphigus and its endemic pemphigus foliaceus (Fogo Selvagem) phenotype: A paradigm of human autoimmunity. <i>Journal of Autoimmunity</i> , 2008, 31, 311-324.	3.0	86
174	Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. <i>Journal of Autoimmunity</i> , 2008, 31, 331-338.	3.0	120
175	Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 1043-1046.	0.6	464
176	Autoantibodies in the Autoimmune Disease Pemphigus Foliaceus Induce Blistering via p38 Mitogen-Activated Protein Kinase-Dependent Signaling in the Skin. <i>American Journal of Pathology</i> , 2008, 173, 1628-1636.	1.9	79
177	Pemphigus Foliaceus. , 2008, 10, 182-194.		14
178	Analysis of Fluorouracil-Based Adjuvant Chemotherapy and Radiation After Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreas: Results of a Large, Prospectively Collected Database at the Johns Hopkins Hospital. <i>Journal of Clinical Oncology</i> , 2008, 26, 3503-3510.	0.8	343
179	Epidemiology and Immunogenetics of Autoimmune Bullous Diseases. <i>Journal of Investigative Dermatology</i> , 2008, 128, E31-E32.	0.3	1
180	Dissecting the Anti-Desmoglein Autoreactive B Cell Repertoire in Pemphigus Vulgaris Patients. <i>Journal of Immunology</i> , 2007, 178, 5982-5990.	0.4	23

#	ARTICLE	IF	CITATIONS
181	Rituximab and Pemphigus " A Therapeutic Advance. <i>New England Journal of Medicine</i> , 2007, 357, 605-607.	13.9	8
182	Serial Assessment of Human Tumor Burdens in Mice by the Analysis of Circulating DNA. <i>Cancer Research</i> , 2007, 67, 9364-9370.	0.4	147
183	Targeting Cancer with Bugs and Liposomes: Ready, Aim, Fire. <i>Cancer Research</i> , 2007, 67, 9605-9608.	0.4	29
184	Endemic Pemphigus Vulgaris. <i>Archives of Dermatology</i> , 2007, 143, 895.	1.7	37
185	Digital quantification of mutant DNA in cancer patients. <i>Current Opinion in Oncology</i> , 2007, 19, 36-42.	1.1	45
186	Imaging of Musculoskeletal Bacterial Infections by [124I]FIAU-PET/CT. <i>PLoS ONE</i> , 2007, 2, e1007.	1.1	86
187	Experimental models for the autoimmune and inflammatory blistering disease, Bullous pemphigoid. <i>Archives of Dermatological Research</i> , 2007, 299, 417-422.	1.1	44
188	A Bacterial Protein Enhances the Release and Efficacy of Liposomal Cancer Drugs. <i>Science</i> , 2006, 314, 1308-1311.	6.0	159
189	The genome and transcriptomes of the anti-tumor agent <i>Clostridium novyi-NT</i> . <i>Nature Biotechnology</i> , 2006, 24, 1573-1580.	9.4	128
190	The colorectal microRNAome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 3687-3692.	3.3	890
191	Contribution of bone marrow-derived endothelial cells to human tumor vasculature. <i>Nature Medicine</i> , 2005, 11, 261-262.	15.2	470
192	Cancer drug discovery through collaboration. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 375-380.	21.5	30
193	Mutant PIK3CA promotes cell growth and invasion of human cancer cells. <i>Cancer Cell</i> , 2005, 7, 561-573.	7.7	818
194	The current clinical value of genomic instability. <i>Seminars in Cancer Biology</i> , 2005, 15, 67-71.	4.3	13
195	Detection and quantification of mutations in the plasma of patients with colorectal tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 16368-16373.	3.3	1,049
196	Desmosome Signaling. <i>Journal of Biological Chemistry</i> , 2005, 280, 23778-23784.	1.6	220
197	Pharmacologic and Toxicologic Evaluation of <i>C. novyi-NT</i> Spores. <i>Toxicological Sciences</i> , 2005, 88, 562-575.	1.4	90
198	Imaging bacterial infections with radiolabeled 1-(2'-deoxy-2'-fluoro- β -D-arabinofuranosyl)-5-iodouracil. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 1145-1150.	3.3	125

#	ARTICLE	IF	CITATIONS
199	Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3089-3094.	3.3	175
200	Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15172-15177.	3.3	244
201	Reversible Posterior Leukoencephalopathy in an HIV-infected Patient with Thrombotic Thrombocytopenic Purpura. Scandinavian Journal of Infectious Diseases, 2002, 34, 706-709.	1.5	20
202	INDUCTION OF HLA-DR ANTIGEN ON HUMAN SQUAMOUS CARCINOMA BY RECOMBINANT INTERFERON GAMMA. Laryngoscope, 1988, 98, 511-515.	1.1	9